Index RUT
P/E -
EPS (ttm) -0.19
Insider Own 54.82%
Shs Outstand 682.48M
Perf Week 3.85%
Market Cap 1.11B
Forward P/E -
EPS next Y -0.29
Insider Trans 0.54%
Shs Float 308.38M
Perf Month 10.20%
Income -133.76M
PEG -
EPS next Q -0.09
Inst Own 30.03%
Short Float 28.51%
Perf Quarter 11.72%
Sales 711.40M
P/S 1.55
EPS this Y 28.00%
Inst Trans 3.14%
Short Ratio 22.63
Perf Half Y 8.00%
Book/sh 2.06
P/B 0.79
EPS next Y -62.96%
ROA -6.20%
Short Interest 87.92M
Perf Year 58.82%
Cash/sh 0.60
P/C 2.72
EPS next 5Y 20.98%
ROE -9.39%
52W Range 0.86 - 1.76
Perf YTD 10.20%
Dividend Est. -
P/FCF -
EPS past 5Y 1.56%
ROI -7.09%
52W High -7.95%
Beta 1.73
Dividend TTM -
Quick Ratio 2.69
Sales past 5Y 6.34%
Gross Margin 13.32%
52W Low 88.35%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 2.97
EPS Y/Y TTM 33.72%
Oper. Margin -43.51%
RSI (14) 62.51
Volatility 3.63% 3.51%
Employees 3930
Debt/Eq 0.37
Sales Y/Y TTM -17.95%
Profit Margin -18.80%
Recom 1.00
Target Price 3.96
Option/Short Yes / Yes
LT Debt/Eq 0.35
EPS Q/Q 122.15%
Payout -
Rel Volume 0.50
Prev Close 1.65
Sales Surprise -4.37%
EPS Surprise 132.15%
Sales Q/Q -2.78%
Earnings Nov 07 AMC
Avg Volume 3.88M
Price 1.62
SMA20 6.23%
SMA50 5.76%
SMA200 10.88%
Trades
Volume 1,942,918
Change -1.82%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-29-23 Upgrade
Barrington Research
Mkt Perform → Outperform
$2
Dec-15-22 Initiated
H.C. Wainwright
Buy
$3
Jan-24-22 Downgrade
Barrington Research
Outperform → Mkt Perform
Jun-21-21 Initiated
Ladenburg Thalmann
Buy
$7
Nov-25-19 Initiated
Piper Jaffray
Overweight
$2.50
Mar-02-18 Downgrade
JP Morgan
Neutral → Underweight
Sep-14-17 Downgrade
JP Morgan
Overweight → Neutral
Jun-21-16 Reiterated
Standpoint Research
Buy
$16 → $18
Jun-03-16 Initiated
Standpoint Research
Buy
$16
Mar-31-16 Reiterated
Barrington Research
Outperform
$17 → $16
Oct-16-15 Initiated
JP Morgan
Overweight
$14
Sep-11-15 Downgrade
Jefferies
Buy → Hold
Mar-03-15 Downgrade
Oppenheimer
Outperform → Perform
May-12-14 Reiterated
Oppenheimer
Outperform
$13 → $12
Mar-14-14 Initiated
Oppenheimer
Outperform
$13
Nov-13-13 Reiterated
Ladenburg Thalmann
Buy
$10 → $14.50
May-30-13 Reiterated
Ladenburg Thalmann
Buy
$8.50 → $10
Oct-22-12 Initiated
Barrington Research
Outperform
$6
Dec-01-11 Reiterated
Ladenburg Thalmann
Buy
$6 → $8.50
Jul-14-11 Initiated
Ladenburg Thalmann
Buy
$6
Show Previous Ratings
Jan-27-25 08:00AM
Jan-20-25 10:02PM
Jan-09-25 11:45AM
Jan-07-25 08:00AM
Dec-11-24 02:08AM
08:00AM
Loading…
Dec-10-24 08:00AM
Nov-29-24 02:43PM
Nov-20-24 08:00AM
Nov-18-24 08:00AM
Nov-15-24 08:34PM
Nov-14-24 06:00AM
Nov-08-24 04:05PM
04:01AM
Nov-07-24 10:15PM
08:00PM
06:40PM
Loading…
06:40PM
05:35PM
(Associated Press Finance)
04:05PM
08:00AM
Oct-29-24 04:05PM
(GlobeNewswire) +6.67%
-5.00%
Oct-07-24 08:00AM
08:00AM
Sep-25-24 08:30AM
Sep-23-24 08:00AM
Sep-16-24 07:30AM
Aug-09-24 04:05PM
Aug-08-24 12:14PM
12:15AM
Aug-07-24 08:00PM
06:59PM
(Associated Press Finance)
04:06PM
Loading…
04:06PM
Aug-01-24 04:05PM
Jul-18-24 08:00AM
Jul-17-24 04:14PM
Jul-08-24 06:54PM
12:30PM
Jul-02-24 08:00AM
Jun-06-24 11:31AM
May-31-24 10:48AM
10:00AM
May-12-24 03:24PM
May-09-24 09:18AM
May-08-24 11:47AM
06:56AM
(Thomson Reuters StreetEvents)
03:44AM
May-07-24 09:15PM
08:30PM
06:09PM
05:30PM
04:38PM
(Associated Press Finance)
04:05PM
May-03-24 08:00AM
Apr-01-24 01:01PM
Mar-28-24 11:08PM
08:00AM
Mar-25-24 09:57AM
Mar-20-24 08:00AM
Mar-05-24 08:52AM
Feb-29-24 08:31AM
Feb-28-24 09:31AM
09:02AM
06:18AM
(Thomson Reuters StreetEvents)
Feb-27-24 09:00PM
07:30PM
06:10PM
05:08PM
(Associated Press Finance)
04:43PM
04:05PM
Feb-26-24 09:16AM
Feb-22-24 04:05PM
Feb-08-24 01:48PM
Feb-05-24 08:09AM
Jan-22-24 11:48AM
Jan-09-24 04:05PM
Jan-08-24 08:00AM
Jan-04-24 11:31PM
Jan-03-24 05:05PM
Dec-07-23 10:20AM
Dec-06-23 11:30AM
Nov-28-23 07:00AM
Nov-07-23 10:36AM
(Thomson Reuters StreetEvents)
10:29AM
09:19AM
06:45AM
01:00AM
Nov-06-23 07:30PM
05:30PM
(Associated Press Finance)
05:01PM
04:05PM
Nov-02-23 10:00AM
Oct-31-23 08:00AM
Oct-25-23 04:25PM
Oct-12-23 10:50AM
Oct-06-23 12:03PM
Sep-29-23 01:03PM
Sep-28-23 07:36PM
04:08PM
Sep-13-23 01:18PM
Sep-12-23 08:30AM
Aug-28-23 11:56AM
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
FROST PHILLIP MD ET AL CEO & Chairman Jan 28 '25 Buy 1.47 47,537 70,060 213,234,014 Jan 28 05:40 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 17 '25 Buy 1.47 150,000 220,425 213,186,477 Jan 17 05:06 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 15 '25 Buy 1.48 500,000 740,850 213,036,477 Jan 15 05:18 PM FROST PHILLIP MD ET AL CEO & Chairman Dec 13 '24 Buy 1.59 125,000 199,375 212,536,477 Dec 13 05:04 PM FROST PHILLIP MD ET AL CEO & Chairman Dec 11 '24 Buy 1.56 500,000 781,050 212,411,477 Dec 11 05:21 PM FROST PHILLIP MD ET AL CEO & Chairman Nov 29 '24 Buy 1.53 199,072 305,376 211,911,477 Nov 29 03:20 PM FROST PHILLIP MD ET AL CEO & Chairman Nov 22 '24 Buy 1.59 100,000 159,000 211,712,405 Nov 22 05:17 PM FROST PHILLIP MD ET AL CEO & Chairman Nov 14 '24 Buy 1.62 100,000 161,980 211,612,405 Nov 14 05:51 PM FROST PHILLIP MD ET AL CEO & Chairman Nov 08 '24 Buy 1.50 280,183 421,535 211,512,405 Nov 08 05:40 PM OPKO HEALTH, INC. 10% Owner Sep 17 '24 Proposed Sale 40.88 13,404 547,956 Sep 20 02:56 PM OPKO HEALTH, INC. 10% Owner Aug 19 '24 Sale 34.49 50,000 1,724,520 2,646,972 Aug 19 05:23 PM OPKO HEALTH, INC. 10% Owner Aug 16 '24 Sale 34.30 50,000 1,714,850 2,696,972 Aug 19 05:23 PM OPKO HEALTH, INC. 10% Owner Aug 15 '24 Sale 33.08 39,824 1,317,505 2,746,972 Aug 19 05:23 PM OPKO HEALTH, INC. 10% Owner Aug 12 '24 Sale 33.95 59,787 2,029,811 2,811,783 Aug 14 04:50 PM OPKO HEALTH, INC. 10% Owner Aug 13 '24 Sale 34.76 24,987 868,503 2,786,796 Aug 14 04:50 PM OPKO HEALTH, INC. 10% Owner Aug 08 '24 Sale 31.82 100,000 3,182,380 2,871,570 Aug 08 05:39 PM OPKO HEALTH, INC. 10% Owner Aug 06 '24 Sale 29.35 12,994 381,427 2,971,570 Aug 08 05:39 PM OPKO HEALTH, INC. 10% Owner Jul 31 '24 Sale 33.50 88,839 2,976,346 2,984,564 Aug 02 04:21 PM OPKO HEALTH, INC. 10% Owner Jul 29 '24 Sale 33.86 50,000 1,692,890 3,073,403 Jul 31 05:03 PM OPKO HEALTH, INC. 10% Owner Jul 24 '24 Sale 33.72 75,000 2,529,105 3,183,403 Jul 26 07:49 PM OPKO HEALTH, INC. 10% Owner Jul 26 '24 Sale 33.85 60,000 2,031,258 3,123,403 Jul 26 07:49 PM OPKO HEALTH, INC. 10% Owner Jul 23 '24 Sale 33.46 75,000 2,509,245 3,258,403 Jul 23 05:16 PM OPKO HEALTH, INC. 10% Owner Jul 22 '24 Sale 32.61 50,000 1,630,440 3,333,403 Jul 23 05:16 PM OPKO HEALTH, INC. 10% Owner Jul 19 '24 Sale 32.29 25,000 807,250 3,383,403 Jul 23 05:16 PM OPKO HEALTH, INC. 10% Owner Jul 17 '24 Sale 32.93 25,000 823,188 3,408,403 Jul 19 06:46 PM OPKO HEALTH, INC. 10% Owner Jul 05 '24 Sale 28.24 36,118 1,020,016 3,433,403 Jul 09 04:07 PM OPKO HEALTH, INC. 10% Owner Jul 01 '24 Sale 26.63 50,000 1,331,700 3,508,603 Jul 03 04:56 PM OPKO HEALTH, INC. 10% Owner Jul 02 '24 Sale 29.12 25,000 728,095 3,483,603 Jul 03 04:56 PM OPKO HEALTH, INC. 10% Owner Jul 03 '24 Sale 28.23 14,082 397,491 3,469,521 Jul 03 04:56 PM FROST PHILLIP MD ET AL CEO & Chairman May 23 '24 Buy 1.27 100,000 126,937 211,232,222 May 23 08:04 PM FROST PHILLIP MD ET AL CEO & Chairman May 17 '24 Buy 1.29 163,997 211,195 211,132,222 May 17 05:31 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 18 '24 Buy 0.87 500,000 437,100 210,968,225 Mar 18 04:45 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 14 '24 Buy 0.89 500,000 444,300 210,468,225 Mar 14 05:00 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 13 '24 Buy 0.93 500,000 463,750 209,968,225 Mar 13 04:44 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 12 '24 Buy 0.93 600,000 559,380 209,468,225 Mar 12 05:27 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 28 '24 Buy 0.99 500,000 496,150 208,868,225 Feb 28 05:31 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 21 '24 Buy 0.99 1,000,000 991,700 208,368,225 Feb 21 05:10 PM
Index -
P/E -
EPS (ttm) -4.16
Insider Own 17.17%
Shs Outstand 4.52M
Perf Week -2.33%
Market Cap 11.50M
Forward P/E -
EPS next Y -1.31
Insider Trans 0.09%
Shs Float 3.80M
Perf Month 18.04%
Income -7.72M
PEG -
EPS next Q -0.62
Inst Own 2.76%
Short Float 0.84%
Perf Quarter 6.10%
Sales 0.07M
P/S 164.32
EPS this Y 62.30%
Inst Trans 16.27%
Short Ratio 0.65
Perf Half Y -6.34%
Book/sh 0.61
P/B 4.12
EPS next Y 57.88%
ROA -154.22%
Short Interest 0.03M
Perf Year -58.39%
Cash/sh 1.08
P/C 2.33
EPS next 5Y 44.44%
ROE -737.89%
52W Range 1.62 - 8.85
Perf YTD 15.14%
Dividend Est. -
P/FCF -
EPS past 5Y 30.13%
ROI -225.33%
52W High -71.64%
Beta 1.26
Dividend TTM -
Quick Ratio 1.78
Sales past 5Y 122.23%
Gross Margin -498.59%
52W Low 54.46%
ATR (14) 0.24
Dividend Ex-Date -
Current Ratio 1.78
EPS Y/Y TTM 55.71%
Oper. Margin -10935.21%
RSI (14) 57.91
Volatility 11.44% 10.83%
Employees 20
Debt/Eq 0.38
Sales Y/Y TTM -87.54%
Profit Margin -10876.06%
Recom 1.00
Target Price 15.50
Option/Short No / Yes
LT Debt/Eq 0.24
EPS Q/Q 65.61%
Payout -
Rel Volume 1.88
Prev Close 2.30
Sales Surprise -100.00%
EPS Surprise 48.74%
Sales Q/Q -100.00%
Earnings Nov 13 AMC
Avg Volume 49.25K
Price 2.51
SMA20 8.64%
SMA50 12.28%
SMA200 -17.52%
Trades
Volume 92,640
Change 9.13%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-21 Downgrade
Dawson James
Buy → Neutral
Jan-31-25 07:16AM
Jan-27-25 09:15AM
Dec-17-24 07:00AM
Dec-04-24 08:30AM
Nov-14-24 02:13AM
04:05PM
Loading…
Nov-13-24 04:05PM
Nov-06-24 07:00AM
Oct-28-24 09:00AM
Oct-09-24 06:19PM
Sep-18-24 08:30AM
Sep-09-24 04:05PM
(GlobeNewswire) +6.17%
+6.64%
Aug-30-24 08:00AM
Aug-29-24 08:30AM
Aug-21-24 07:00AM
Aug-13-24 04:30PM
07:00AM
Loading…
Aug-07-24 07:00AM
Jul-30-24 07:00AM
Jul-25-24 07:00AM
Jul-17-24 07:00AM
Jul-08-24 07:00AM
Jun-10-24 07:32AM
Jun-07-24 07:00AM
Jun-04-24 07:52AM
May-21-24 05:00PM
May-15-24 03:08AM
May-14-24 08:56PM
04:02PM
May-09-24 07:00AM
May-01-24 07:00AM
Apr-25-24 09:00AM
05:41PM
Loading…
Apr-02-24 05:41PM
Apr-01-24 02:30PM
Mar-28-24 05:58AM
(Thomson Reuters StreetEvents)
Mar-27-24 08:53PM
04:00PM
Mar-20-24 07:00AM
Mar-13-24 07:00AM
Mar-12-24 07:00AM
Mar-04-24 09:27AM
(FierceBiotech.com) -21.51%
08:00AM
Feb-08-24 07:00AM
Jan-31-24 07:00AM
Jan-03-24 07:00AM
Dec-19-23 07:00AM
Dec-18-23 07:16AM
Nov-29-23 07:00AM
Nov-16-23 12:56PM
Nov-15-23 11:04AM
Nov-14-23 07:15AM
Nov-09-23 12:48PM
06:59AM
(Thomson Reuters StreetEvents)
Nov-08-23 05:52PM
05:50PM
04:11PM
Nov-01-23 05:04PM
Oct-12-23 11:08AM
Oct-11-23 06:00AM
Sep-06-23 10:31AM
07:15AM
Sep-05-23 07:15AM
Aug-11-23 09:29AM
Aug-09-23 06:05PM
04:05PM
Aug-02-23 07:00AM
Jul-24-23 07:00AM
Jul-10-23 08:11AM
Jul-05-23 07:00AM
Jun-20-23 05:14PM
(GlobeNewswire) +6.41%
+12.45%
Jun-08-23 07:00AM
May-28-23 08:08AM
May-23-23 07:00AM
May-12-23 06:06AM
May-10-23 05:45PM
04:05PM
May-09-23 07:00AM
May-03-23 08:00PM
Apr-28-23 07:00AM
Apr-04-23 07:00AM
Apr-01-23 12:47PM
Mar-31-23 06:05AM
Mar-29-23 08:15AM
Mar-16-23 07:00AM
Mar-06-23 01:06PM
07:00AM
Feb-01-23 06:30AM
Jan-31-23 05:39AM
Dec-22-22 07:00AM
Dec-21-22 05:07AM
Dec-15-22 07:00AM
Dec-06-22 07:00AM
Nov-09-22 05:35PM
04:05PM
12:00PM
Nov-02-22 05:31PM
Oct-03-22 01:33PM
07:00AM
Sep-14-22 07:00AM
Sep-09-22 07:00AM
Sep-08-22 07:00AM
Sep-06-22 11:03AM
BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Altman Peter President and CEO Feb 07 '25 Buy 2.48 600 1,488 107,920 Feb 11 05:42 PM Altman Peter President and CEO Jan 29 '25 Buy 2.40 500 1,200 107,081 Jan 30 08:36 PM Altman Peter President and CEO Jan 30 '25 Buy 2.38 239 569 107,320 Jan 30 08:36 PM Altman Peter President and CEO Dec 23 '24 Buy 2.06 1,000 2,060 106,581 Dec 26 02:30 PM GILLIS EDWARD M Senior Vice President, Devices Dec 20 '24 Sale 2.00 3,257 6,514 8,968 Dec 26 02:30 PM GILLIS EDWARD M Officer Dec 17 '24 Proposed Sale 2.03 3,257 6,611 Dec 17 11:50 AM Altman Peter President and CEO Dec 05 '24 Buy 2.22 250 555 105,581 Dec 09 05:04 PM Altman Peter President and CEO Nov 15 '24 Buy 1.87 1,350 2,524 105,331 Nov 19 08:00 AM Altman Peter President and CEO Jul 01 '24 Buy 3.05 300 915 39,745 Jul 02 04:12 PM Altman Peter President and CEO Jun 28 '24 Buy 2.99 200 598 39,445 Jul 02 04:12 PM Altman Peter President and CEO Jun 21 '24 Buy 3.29 500 1,645 39,245 Jun 24 08:46 AM Altman Peter President and CEO Jun 14 '24 Buy 3.52 500 1,760 38,745 Jun 17 07:00 AM Altman Peter President and CEO Jun 10 '24 Buy 3.36 1,000 3,360 38,245 Jun 12 07:00 AM Altman Peter President and CEO Apr 19 '24 Buy 0.37 2,750 1,013 558,697 Apr 19 05:38 PM Altman Peter President and CEO Mar 28 '24 Buy 0.39 500 195 555,947 Mar 28 07:33 PM Altman Peter President and CEO Feb 13 '24 Buy 0.46 108,108 50,000 555,447 Feb 15 07:00 AM
Index -
P/E -
EPS (ttm) -1.82
Insider Own 54.23%
Shs Outstand 16.88M
Perf Week 5.50%
Market Cap 57.59M
Forward P/E -
EPS next Y -0.53
Insider Trans -0.01%
Shs Float 8.86M
Perf Month 13.12%
Income -27.75M
PEG -
EPS next Q -0.23
Inst Own 29.03%
Short Float 0.33%
Perf Quarter 1.19%
Sales 261.98M
P/S 0.22
EPS this Y -142.59%
Inst Trans 84.06%
Short Ratio 1.59
Perf Half Y 5.50%
Book/sh 1.18
P/B 2.51
EPS next Y 59.92%
ROA -26.67%
Short Interest 0.03M
Perf Year -4.08%
Cash/sh 0.34
P/C 8.74
EPS next 5Y -
ROE -100.04%
52W Range 2.31 - 4.30
Perf YTD 18.06%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -108.85%
52W High -30.80%
Beta 2.30
Dividend TTM -
Quick Ratio 0.94
Sales past 5Y 2.15%
Gross Margin 21.93%
52W Low 28.82%
ATR (14) 0.15
Dividend Ex-Date -
Current Ratio 0.94
EPS Y/Y TTM 80.69%
Oper. Margin -5.33%
RSI (14) 58.06
Volatility 6.39% 4.77%
Employees 277
Debt/Eq 2.02
Sales Y/Y TTM -15.57%
Profit Margin -10.59%
Recom 3.00
Target Price 4.00
Option/Short No / Yes
LT Debt/Eq 0.28
EPS Q/Q 80.17%
Payout -
Rel Volume 0.30
Prev Close 2.92
Sales Surprise -5.99%
EPS Surprise -193.33%
Sales Q/Q -2.60%
Earnings Nov 14 AMC
Avg Volume 18.15K
Price 2.97
SMA20 3.68%
SMA50 7.19%
SMA200 -4.45%
Trades
Volume 5,451
Change 1.88%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-22 Upgrade
Barrington Research
Mkt Perform → Outperform
$2.50
Mar-17-21 Downgrade
Barrington Research
Outperform → Mkt Perform
Nov-02-20 Upgrade
Barrington Research
Mkt Perform → Outperform
$4.50
Aug-26-20 Initiated
Canaccord Genuity
Buy
$5
Nov-12-19 Downgrade
Barrington Research
Outperform → Mkt Perform
May-09-19 Upgrade
ROTH Capital
Neutral → Buy
$5.50 → $8.50
Feb-05-25 08:30AM
Jan-27-25 12:00PM
Jan-17-25 03:34PM
Jan-07-25 08:30AM
Dec-06-24 03:17PM
05:58PM
Loading…
Nov-29-24 05:58PM
Nov-19-24 04:00PM
Nov-15-24 01:04PM
(Thomson Reuters StreetEvents) -6.62%
02:15AM
Nov-14-24 05:12PM
(Associated Press Finance)
04:15PM
Nov-13-24 02:30PM
Sep-10-24 10:00AM
Sep-06-24 08:30AM
Aug-22-24 09:40AM
08:11AM
Loading…
Aug-20-24 08:11AM
(Thomson Reuters StreetEvents) -9.67%
Aug-19-24 05:10PM
04:00PM
Aug-15-24 10:00AM
Jul-12-24 08:30AM
Jun-28-24 08:30AM
May-28-24 09:40AM
May-16-24 11:39AM
(Thomson Reuters StreetEvents) -13.10%
08:16AM
07:34AM
03:07AM
May-15-24 08:52PM
04:45PM
(Associated Press Finance)
04:15PM
May-09-24 01:19PM
07:00AM
Loading…
May-02-24 07:00AM
Apr-10-24 08:00AM
Apr-03-24 09:00AM
06:44AM
(Thomson Reuters StreetEvents)
Apr-02-24 05:32PM
Apr-01-24 10:48PM
Mar-21-24 09:00AM
Feb-29-24 02:25PM
12:22PM
Feb-27-24 09:00AM
Jan-25-24 08:30AM
Nov-15-23 09:55AM
(Thomson Reuters StreetEvents) -16.50%
Nov-14-23 05:11PM
04:54PM
(Associated Press Finance)
04:15PM
Nov-03-23 03:00PM
Aug-22-23 08:30AM
Aug-15-23 12:04PM
06:05AM
(Thomson Reuters StreetEvents)
Aug-14-23 04:30PM
Aug-09-23 09:09PM
Aug-08-23 08:30AM
Aug-02-23 08:30AM
Aug-01-23 03:30PM
Jul-27-23 08:30AM
Jul-10-23 10:14AM
Jun-13-23 08:42AM
May-17-23 06:15AM
May-16-23 08:01AM
(Thomson Reuters StreetEvents) -20.19%
May-15-23 04:15PM
May-12-23 02:10PM
May-11-23 09:40AM
May-02-23 05:50PM
08:30AM
May-01-23 09:00AM
Apr-26-23 05:50PM
Apr-20-23 05:50PM
Apr-18-23 10:02AM
09:00AM
Apr-07-23 09:35AM
Apr-06-23 08:30AM
Apr-05-23 09:40AM
Mar-20-23 09:40AM
05:33AM
Mar-18-23 03:12AM
Mar-17-23 06:16AM
Mar-16-23 05:53AM
(Thomson Reuters StreetEvents) -32.63%
Mar-15-23 04:15PM
Feb-27-23 09:00AM
Feb-08-23 09:40AM
Jan-25-23 05:50AM
Jan-20-23 09:40AM
Jan-15-23 03:10PM
Dec-22-22 07:38AM
Nov-07-22 04:01PM
Oct-26-22 08:30AM
Oct-19-22 07:53AM
Oct-17-22 08:30AM
Oct-11-22 08:30AM
Oct-05-22 08:30AM
Sep-14-22 06:30AM
Sep-13-22 08:30AM
Aug-18-22 06:16AM
Aug-09-22 08:00PM
(Motley Fool) -8.16%
+9.63%
05:55PM
04:30PM
(Thomson Reuters StreetEvents)
04:01PM
Aug-08-22 11:30AM
Aug-04-22 05:51PM
Jul-22-22 08:50AM
Fluent, Inc. engages in the provision of digital marketing services. It operates through the Fluent and All Other segments. The Fluent segment includes delivering data and performance-based marketing executions. The All Other segment represents the operation results of AdParlor, LLC, a digital advertising solution for social media buying. The company was founded by Ryan Schulke and Matthew Conlin in 2001 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Patrick Donald Huntley Chief Executive Officer Sep 12 '24 Sale 2.67 20,250 54,068 329,063 Dec 16 04:16 PM GLOBAL VALUE INVESTMENT CORP. 10% Owner Dec 05 '24 Buy 2.69 14,337 38,554 3,056,403 Dec 06 04:30 PM GLOBAL VALUE INVESTMENT CORP. 10% Owner Dec 04 '24 Buy 2.74 5,045 13,826 3,042,066 Dec 06 04:30 PM Patrick Donald Huntley Chief Executive Officer Jul 17 '24 Option Exercise 0.00 29,551 15 349,313 Jul 17 06:20 PM Conlin Matthew Chief Customer Officer Jul 17 '24 Option Exercise 0.00 487,589 244 1,601,164 Jul 17 05:00 PM Conlin Matthew Chief Customer Officer Jul 17 '24 Option Exercise 0.00 73,877 37 125,039 Jul 17 05:00 PM Schulke Ryan Chief Strategy Officer Jul 09 '24 Option Exercise 0.00 1,743,499 872 2,941,164 Jul 11 12:40 PM Schulke Ryan Chief Strategy Officer Jun 14 '24 Buy 3.42 3,000 10,246 103,027 Jun 18 04:43 PM Schulke Ryan Chief Strategy Officer Mar 14 '24 Buy 0.53 21,000 11,128 600,159 Mar 14 05:57 PM Schulke Ryan Chief Strategy Officer Mar 13 '24 Buy 0.53 10,000 5,299 579,159 Mar 14 05:57 PM Perfit Ryan MacNab Interim CFO Mar 11 '24 Buy 0.58 10,000 5,787 45,596 Mar 12 06:26 PM Perfit Ryan MacNab Interim CFO Mar 08 '24 Buy 0.57 596 340 35,596 Mar 12 06:26 PM Schulke Ryan Chief Strategy Officer Mar 12 '24 Buy 0.59 20,000 11,858 569,159 Mar 12 06:17 PM Schulke Ryan Chief Strategy Officer Mar 08 '24 Buy 0.62 10,000 6,187 549,159 Mar 11 09:43 PM Schulke Ryan Chief Strategy Officer Mar 07 '24 Buy 0.59 10,000 5,900 539,159 Mar 07 05:43 PM Perfit Ryan MacNab Interim CFO Mar 04 '24 Buy 0.59 10,000 5,900 35,000 Mar 06 06:25 PM Schulke Ryan Chief Strategy Officer Mar 04 '24 Buy 0.60 10,000 5,973 509,159 Mar 06 06:25 PM Schulke Ryan Chief Strategy Officer Mar 05 '24 Buy 0.53 10,000 5,336 519,159 Mar 06 06:25 PM Schulke Ryan Chief Strategy Officer Mar 06 '24 Buy 0.52 10,000 5,201 529,159 Mar 06 06:25 PM
Index -
P/E -
EPS (ttm) -1.84
Insider Own 31.67%
Shs Outstand 10.17M
Perf Week 12.69%
Market Cap 22.59M
Forward P/E -
EPS next Y -2.16
Insider Trans 0.00%
Shs Float 6.95M
Perf Month 0.45%
Income -18.70M
PEG -
EPS next Q -0.53
Inst Own 7.07%
Short Float 0.27%
Perf Quarter 30.59%
Sales 0.00M
P/S -
EPS this Y -3.21%
Inst Trans 6.68%
Short Ratio 0.41
Perf Half Y 23.54%
Book/sh 1.25
P/B 1.78
EPS next Y -11.92%
ROA -76.57%
Short Interest 0.02M
Perf Year 48.00%
Cash/sh 1.29
P/C 1.72
EPS next 5Y -11.32%
ROE -86.20%
52W Range 1.33 - 3.26
Perf YTD 9.90%
Dividend Est. -
P/FCF -
EPS past 5Y -1.25%
ROI -130.92%
52W High -31.90%
Beta 2.33
Dividend TTM -
Quick Ratio 7.32
Sales past 5Y -42.33%
Gross Margin -
52W Low 67.55%
ATR (14) 0.20
Dividend Ex-Date -
Current Ratio 7.32
EPS Y/Y TTM 8.73%
Oper. Margin -
RSI (14) 55.52
Volatility 10.22% 8.53%
Employees 12
Debt/Eq 0.15
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 8.33
Option/Short No / Yes
LT Debt/Eq 0.12
EPS Q/Q -18.33%
Payout -
Rel Volume 1.14
Prev Close 2.28
Sales Surprise -
EPS Surprise 14.04%
Sales Q/Q -
Earnings Nov 13 BMO
Avg Volume 45.02K
Price 2.22
SMA20 10.60%
SMA50 4.53%
SMA200 9.79%
Trades
Volume 51,309
Change -2.63%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-08-20 Initiated
H.C. Wainwright
Buy
$5
Jan-08-25 08:00AM
Jan-02-25 06:34AM
(Clinical Trials Arena) +14.85%
Dec-31-24 02:03PM
08:00AM
Nov-13-24 08:00AM
08:00AM
Loading…
Oct-31-24 08:00AM
Sep-26-24 08:00AM
Aug-19-24 04:05PM
(GlobeNewswire) +15.38%
-9.05%
Aug-15-24 03:00PM
Aug-14-24 08:00AM
Jul-18-24 08:00AM
Jun-20-24 08:00AM
Jun-07-24 09:55AM
May-13-24 01:53PM
08:00AM
08:00AM
Loading…
May-01-24 08:00AM
Mar-28-24 01:53PM
08:00AM
Mar-19-24 08:00AM
Mar-05-24 08:30AM
Jan-04-24 08:00AM
Dec-06-23 08:00AM
Nov-29-23 08:00AM
Nov-27-23 08:00AM
Nov-13-23 08:00AM
Nov-09-23 08:00AM
Oct-31-23 08:00AM
Oct-02-23 12:14PM
Sep-28-23 08:00AM
Sep-05-23 08:00AM
09:11AM
Loading…
Aug-16-23 09:11AM
Aug-14-23 08:00AM
Aug-08-23 08:00AM
May-31-23 08:00AM
May-17-23 09:26AM
(Zacks Small Cap Research) -5.88%
May-15-23 08:00AM
May-04-23 04:05PM
Apr-24-23 08:00AM
Apr-18-23 08:00AM
Apr-10-23 08:30AM
Mar-31-23 10:05AM
(Zacks Small Cap Research) +5.85%
Mar-29-23 08:00AM
Mar-22-23 01:03PM
(Zacks Small Cap Research)
08:00AM
Jan-26-23 08:00AM
Jan-23-23 09:00AM
Dec-19-22 08:00AM
Dec-01-22 04:05PM
Nov-17-22 01:38PM
08:00AM
Nov-15-22 11:19AM
(Zacks Small Cap Research)
Nov-14-22 08:00AM
Nov-02-22 08:00AM
Nov-01-22 04:05PM
Oct-26-22 08:00AM
Oct-19-22 08:00AM
Oct-13-22 08:00AM
Oct-11-22 11:51AM
08:00AM
Oct-05-22 08:00AM
Oct-03-22 04:05PM
Sep-06-22 10:05AM
08:00AM
Aug-19-22 08:10AM
(Zacks Small Cap Research) -6.42%
Aug-15-22 08:00AM
Aug-08-22 08:00AM
Aug-03-22 09:00AM
Jul-14-22 08:00AM
Jun-01-22 08:00AM
May-18-22 08:00AM
May-12-22 08:12AM
(Zacks Small Cap Research)
May-11-22 08:00AM
Apr-21-22 08:00AM
Apr-19-22 08:00AM
Apr-14-22 08:00AM
Apr-12-22 11:01AM
08:00AM
Apr-06-22 10:15AM
Mar-30-22 02:57PM
Mar-25-22 07:30AM
(Zacks Small Cap Research)
Mar-23-22 04:05PM
Mar-22-22 08:00AM
Mar-10-22 08:00AM
Mar-03-22 08:00AM
Feb-24-22 08:10AM
(Zacks Small Cap Research)
Jan-27-22 12:22PM
08:00AM
Jan-11-22 07:00AM
Jan-10-22 04:10PM
Jan-06-22 08:00AM
Jan-04-22 08:00AM
Dec-22-21 08:00AM
Dec-02-21 08:00AM
Dec-01-21 04:05PM
Nov-15-21 12:25PM
08:00AM
Nov-08-21 03:00PM
08:00AM
Nov-01-21 08:00AM
Oct-21-21 08:00AM
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite